Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury
Shasha Jin1, Xuesong Li2, Yujuan Fan2
1Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China.
Abstract:
Methimazole (MMI) has been used in the therapy of Grave's disease (GD) since 1954, and drug-induced liver injury (DILI) is one of the most deleterious side effects. Genetic polymorphisms of drug-metabolizing enzymes and drug transporters have been associated with drug-induced hepatotoxicity in many cases. The aim of this study was to investigate genetic susceptibility of the drug-metabolizing enzymes and drug transporters to the MMI-DILI. A total of 44 GD patients with MMI-DILI and 118 GD patients without MMI-DILI development were included in the study. Thirty-three single nucleotide polymorphisms (SNPs) in twenty candidate genes were genotyped. We found that rs12422149 of SLCO2B1, rs2032582_AT of ABCB1, rs2306283 of SLCO1B1 and rs4148323 of UGT1A1 exhibited a significant association with MMI-DILI; however, no significant difference existed after Bonferroni correction. Haplotype analysis showed that the frequency of SLCO1B1*1a (388A521T) was significantly higher in MMI-DILI cases than that in the control group (OR = 2.21, 95% CI = 1.11-4.39, P = 0.023), while the frequency of SLCO1B1*1b (388G521T) was significantly higher in the control group (OR = 0.52, 95% CI = 0.29-0.93, P = 0.028). These results suggested that genetic polymorphisms of SLCO1B1 were associated with susceptibility to MMI-DILI. The genetic polymorphism of SLCO1B1 may be important predisposing factors for MMI-induced hepatotoxicity.
Insights
Genetic variations in SLCO1B1 may increase susceptibility to methimazole-induced liver injury in Grave's disease patients. Further research into these genetic factors could help predict and prevent adverse drug reactions.
Area of Science:
- Pharmacogenomics
- Hepatology
- Endocrinology
Background:
- Methimazole (MMI) is a primary treatment for Grave's disease (GD).
- Drug-induced liver injury (DILI) is a significant adverse effect of MMI therapy.
- Genetic factors influencing MMI-DILI susceptibility are not fully understood.
Purpose of the Study:
- To investigate the association between genetic polymorphisms in drug-metabolizing enzymes and transporters and MMI-DILI.
- To identify genetic markers that predict MMI-DILI risk in GD patients.
Main Methods:
- Genotyping of 33 single nucleotide polymorphisms (SNPs) in 20 candidate genes in 44 GD patients with MMI-DILI and 118 controls.
- Association analysis of SNPs with MMI-DILI.
- Haplotype analysis of SLCO1B1 gene.
Main Results:
- Several SNPs (rs12422149 in SLCO2B1, rs2032582_AT in ABCB1, rs2306283 in SLCO1B1, rs4148323 in UGT1A1) showed preliminary association with MMI-DILI, though not significant after Bonferroni correction.
- Haplotype SLCO1B1*1a (388A521T) was more frequent in MMI-DILI cases (OR=2.21).
- Haplotype SLCO1B1*1b (388G521T) was more frequent in the control group (OR=0.52).
Conclusions:
- Genetic polymorphisms in the SLCO1B1 gene are associated with susceptibility to MMI-DILI.
- SLCO1B1 genetic variations may serve as predisposing factors for MMI-induced hepatotoxicity.
Related Concept Videos
Animal Mitochondrial Genetics
Magnetic Susceptibility and Permeability
When diamagnetic materials are placed under an external magnetic field, the moments opposite to the field are induced. Hence, the susceptibility for diamagnets has a minimal negative value of 10-5–10-6. Since...
Single Nucleotide Polymorphisms-SNPs
Association Areas of the Cortex
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
Associative Learning
Classical conditioning, also known...
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...


